NCT00095277View on ClinicalTrials.gov

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 31, 2004

Conditions
Anemia
Interventions
DRUG

Darbepoetin Alfa

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY